Merck KGaA ADR MKKGY
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MKKGY is a good fit for your portfolio.
News
-
Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia
-
Merck KGaA Expects Organic Sales, Earnings Growth This Year
-
Merck KGaA Supervisory Board Elects Michael Kleinemeier as Chair Until Annual Meeting
-
Merck KGaA Supervisory Board Chairman Wolfgang Buechele to Step Down
-
German stocks rise after ending at a record high
-
Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials
-
Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials
-
Merck MS Drug Fails to Meet Target of Late-Stage Trials
Trading Information
- Previous Close Price
- $32.07
- Day Range
- $31.90–32.85
- 52-Week Range
- $28.59–36.89
- Bid/Ask
- $31.75 / $32.99
- Market Cap
- $70.11 Bil
- Volume/Avg
- 49,766 / 107,270
Key Statistics
- Price/Earnings (Normalized)
- 19.83
- Price/Sales
- 3.15
- Dividend Yield (Trailing)
- 1.51%
- Dividend Yield (Forward)
- 1.47%
- Total Yield
- 1.51%
Company Profile
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 62,908
- Website
- https://www.emdgroup.com
Competitors
Valuation
|
Metric
|
MKKGY
|
DHR
|
BIIB
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.83 | 30.42 | 13.93 |
Price/Book Value | 2.43 | 3.41 | 1.99 |
Price/Sales | 3.15 | 8.14 | 3.15 |
Price/Cash Flow | 14.71 | 27.72 | 13.02 |
Price/Earnings
MKKGY
DHR
BIIB
Financial Strength
|
Metric
|
MKKGY
|
DHR
|
BIIB
|
|---|---|---|---|
Quick Ratio | 0.79 | 1.34 | 0.92 |
Current Ratio | 1.42 | 1.85 | 2.00 |
Interest Coverage | 11.32 | 15.85 | 5.13 |
Quick Ratio
MKKGY
DHR
BIIB
Profitability
|
Metric
|
MKKGY
|
DHR
|
BIIB
|
|---|---|---|---|
Return on Assets (Normalized) | 7.55% | 5.15% | 8.32% |
Return on Equity (Normalized) | 13.81% | 8.40% | 15.02% |
Return on Invested Capital (Normalized) | 10.19% | 6.02% | 10.29% |
Return on Assets
MKKGY
DHR
BIIB
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Cnbbghdd | Gpd | $72.4 Bil | |
HLN
| Haleon PLC ADR | Ltnfbqcg | Fhz | $38.2 Bil | |
VTRS
| Viatris Inc | Nxvtsst | Ftyk | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zrrdbdly | Phx | $12.5 Bil | |
CTLT
| Catalent Inc | Vyvxyjsvw | Sqdnksz | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Dtxtvchb | Syxp | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Kqxymxjz | Lnswm | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Gmwkwhzg | Flvbky | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Nqmhldgvb | Psgqm | $2.9 Bil |